CRB-701
CRB-701 is an experimental antibody-drug conjugate from Corbus Pharmaceuticals in phase 2 trials, aimed at Nectin-4.
Overview
CRB-701 is an antibody-drug conjugate developed by Corbus Pharmaceuticals. Its target is Nectin-4 (the sponsor names Nectin-4). ClinicalTrials.gov describes the intervention as: Nectin-4 targeted Antibody Drug Conjugate (ADC). It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial. The largest, NCT06265727, plans to enrol 348 participants with primary completion expected 2027-01-16. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"CRB-701" OR ABSTRACT:"CRB-701") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CRB-701, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentA166
Shares the tags pipeline, ctgov-ingest.
- TreatmentAAA817
Shares the tags pipeline, ctgov-ingest.
- TreatmentABBV-706
Shares the tags pipeline, ctgov-ingest.
- TreatmentAbexinostat
Shares the tags pipeline, ctgov-ingest.
- TreatmentABSK061
Shares the tags pipeline, ctgov-ingest.
- TreatmentABT-301
Shares the tags pipeline, ctgov-ingest.
- TreatmentAcasunlimab
Shares the tags pipeline, ctgov-ingest.
- TreatmentADG126
Shares the tags pipeline, ctgov-ingest.